PR
DNTH icon

PSP Research’s Dianthus Therapeutics DNTH Stock Holding History

PSP Research’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$244K Sell
2,500
-2,500
-50% -$218K 0.13% 60
2026
Q1 		$420K Sell
5,000
-7,725
-61% -$447K 0.3% 44
2025
Q4 		$524K Buy
+12,725
New +$493K 0.46% 56

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

PSP Research's DNTH Position: Q2 2026 in Review

PSP Research reduced its Dianthus Therapeutics (DNTH) stake by 50% in Q2 2026, selling an estimated $218K and leaving 2,500 shares worth $244K. The position accounts for 0.13% of the portfolio, ranked #60.

PSP Research first reported a position in DNTH in Q4 2025 and has held it in 3 quarters since. The position peaked at $524K in Q4 2025. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • PSP Research held 2,500 shares of Dianthus Therapeutics worth $244K as of Q2 2026.
  • PSP Research sold 2,500 Dianthus Therapeutics shares in Q2 2026, an estimated $218K.
  • Dianthus Therapeutics made up 0.13% of PSP Research's portfolio in Q2 2026, its #60 holding.
  • PSP Research first reported a position in Dianthus Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • PSP Research's Dianthus Therapeutics position peaked at $524K in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.